The Molecular Biology/Gene Expression Core Facility will provide critical services to support the scientific goals of this Program Project: 1) Reagent Bank- contains specific plasmids, expression constructs, reporter constructs, antibodies, RNA samples, and retroviral/adenoviral/lentiviral vectors of relevance to the study of esophageal carcinogenesis. As a result, these reagents have been organized and centralized. In addition, we will continue to store newly available reagents;2) Image Analysis and Gene Expression Quantification- multiple instruments are available, such as (but not limited to) Phosphorimaging, Gel and Chemidoc, Agilent Bioanalyzer and Odyssey Infrared Protein Imaging System, real-time quantitative PCR, and transcriptional analysis for Dynex and Orion Luminometers;3) Gene Profiling Services (subsidized) with gene microarrays (Affymetrix platform) through the Penn microarray facility (Dr. Baldwin) and the Penn bioinformatics facility (Dr. Tobias integrated within the Biostatistics Core);4) Human Tissue Bank with an esophageal tissue repository and annotated clinical tissue component;5) Esophageal Cell Line Bank (murine and human) with primary, immortalized, transformed and newly genetically engineered esophageal cell lines for use by the Projects;6) Esophageal database repository (web-based) for esophageal tissues, cell lines (nontransformed and transformed, organotypic cultures, microarrays, and common, shared reagents/equipment (from Cores C and D). The Molecular Biology/Gene Expression Core provides quality assurance, quality control, cost- effectiveness, timeliness and efficiency in its services. All components that pertain to human tissues are IRB approved with patient informed consent and HIPAA compliance, and carry patient de-identifiers. This Core works closely with all the other Cores, especially the Morphology Core C to avoid duplication and furnish coordinated approaches for the Projects. The Projects benefit tremendously from this Core in advancing their interrelated hypotheses and Specific Aims. In addition, this Core is dynamic in responding to evolving P01 needs, anticipating future P01 directions, and integrating emerging technologies.
(Seeinstructions):
| Facompre, Nicole D; Harmeyer, Kayla M; Sahu, Varun et al. (2018) Targeting JARID1B's demethylase activity blocks a subset of its functions in oral cancer. Oncotarget 9:8985-8998 |
| Deng, Jiehui; Wang, Eric S; Jenkins, Russell W et al. (2018) CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov 8:216-233 |
| Karakasheva, Tatiana A; Lin, Eric W; Tang, Qiaosi et al. (2018) IL-6 Mediates Cross-Talk between Tumor Cells and Activated Fibroblasts in the Tumor Microenvironment. Cancer Res 78:4957-4970 |
| Kasagi, Yuta; Chandramouleeswaran, Prasanna M; Whelan, Kelly A et al. (2018) The Esophageal Organoid System Reveals Functional Interplay Between Notch and Cytokines in Reactive Epithelial Changes. Cell Mol Gastroenterol Hepatol 5:333-352 |
| Pectasides, Eirini; Stachler, Matthew D; Derks, Sarah et al. (2018) Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov 8:37-48 |
| Campbell, Joshua D; Yau, Christina; Bowlby, Reanne et al. (2018) Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Rep 23:194-212.e6 |
| Whelan, Kelly A; Muir, Amanda B; Nakagawa, Hiroshi (2018) Esophageal 3D Culture Systems as Modeling Tools in Esophageal Epithelial Pathobiology and Personalized Medicine. Cell Mol Gastroenterol Hepatol 5:461-478 |
| Giroux, Véronique; Stephan, Julien; Chatterji, Priya et al. (2018) Mouse Intestinal Krt15+ Crypt Cells Are Radio-Resistant and Tumor Initiating. Stem Cell Reports 10:1947-1958 |
| Barnoud, Thibaut; Budina-Kolomets, Anna; Basu, Subhasree et al. (2018) Tailoring Chemotherapy for the African-Centric S47 Variant of TP53. Cancer Res 78:5694-5705 |
| Adeegbe, Dennis O; Liu, Shengwu; Hattersley, Maureen M et al. (2018) BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer. Cancer Immunol Res 6:1234-1245 |
Showing the most recent 10 out of 173 publications
